Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$110.9MCash on Hand
38.9mo Cash Runway
Follow NBTX by emailGet an email when NBTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NBTX, unsubscribe in one click. Privacy
📣 What NBTX Says Is Next
second half of 2026 · “While Part 1 data for CONVERGE provides promising signals, the MD Anderson NSCLC reirradiation trial—which evaluates one of the most difficult-to-treat and resistant NSCLC populations—has also shown positive efficacy signals that could suggest a larger potential impact of JNJ-1900 (NBTXR3) in earlier lines of treatment, with final 24-patient data expected in the second half of 2026.”
Company press release, May 20, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Shareholder vote Nanobiotix reported total voting rights of 54,726,179 theoretical and 54,704,061 exercisable as of October 31, 2026, against 50,968,893 shares outstanding. The figures are published as required under French disclosure rules. Form 6-K · SEC filing · Press release
Nov 9, 2026 ·
Nanobiotix will present at the Jefferies Global Healthcare Conference in London on November 16, 2026, with CEO Laurent Levy and CFO Arnd Christ, and at the UBS Global Biopharma Conference in London on November 17, 2026. Form 6-K · SEC filing · Press release
Oct 26, 2026 ·
Clinical trial Final Phase 1 data for JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in 24 anti-PD-1-resistant primary cutaneous melanoma patients showed a 41.7% (10/24) overall response rate, including 4 complete responses, a 75% (18/24) disease control rate and 17.8 months median overall survival. Form 6-K · SEC filing · Press release
Oct 20, 2026 ·
Nanobiotix reported voting rights and share capital as of September 30, 2026: 50,967,610 shares outstanding, 54,729,543 theoretical voting rights and 54,707,425 exercisable voting rights. Form 6-K · SEC filing · Press release
Oct 1, 2026 ·
Leadership Nanobiotix appointed Arnd Christ as chief financial officer and executive board member, effective October 1, 2026. He succeeds Bart Van Rhijn, who steps down after five years of service. Christ was previously CFO of Immatics N.V. from October 2020 to September 2025. Form 6-K · SEC filing · Press release
Sep 24, 2026 ·
Clinical trial Reported H1 2026 net loss of €34.3M (€0.70 per share) and cash of €110.9M, saying it funds operations into 2029. Phase 1 NSCLC data showed 79% one-year locoregional control. Phase 3 NANORAY-312 protocol was amended, removing the interim analysis. Form 6-K · SEC filing · Press release
Sep 22, 2026 ·
Nanobiotix reported voting rights and share capital as of August 31, 2026: 50,941,528 shares outstanding, 54,701,246 theoretical voting rights and 54,679,128 exercisable voting rights. Form 6-K · SEC filing · Press release
Sep 14, 2026 ·
Clinical trial Nanobiotix reported full-cohort Phase 1 results for JNJ-1900 (NBTXR3) in inoperable recurrent non-small cell lung cancer: all 24 patients completed treatment with no dose-limiting toxicities and no Grade 3+ adverse events related to the drug or injection. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2027 · Phase 1 · Active Trial · NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not NBTX's own candidates): Nivolumab, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NBTX holds $110.9M in cash and short-term investments and burns about $8.5M/quarter from operations,
an estimated runway of 38.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:0 · Low
Cash runway 39 months
Shelf registration (F-3, Mar 2025) +10
Raised after last reported balance sheet (May 2026) -10
Share count 48,410,068 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NBTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NBTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.